Stimulating progress


Neuromod Devices is committed to advancing tinnitus care through the research, development and clinical evaluation of bimodal neuromodulation, and through the continued clinical education, training and support of its hearing healthcare providers.

Since 2010, Neuromod has worked to become the category-defining company for the treatment of tinnitus with bimodal neuromodulation through scientific understanding, clinical validation and commercial excellence. Neuromod Devices partners with a network of leading international tinnitus experts to deliver standard-setting tinnitus treatment with Lenire. Lenire Partners grow their practice through frictionless onboarding, a robust library of clinical and commercial content, and effortless procurement through our global supply chain.

Stimulating Leadership


Neuromod Devices’ management and board includes neuroscientists, audiologists, ENTs, engineers, regulatory specialists and industry experts.

They are recognised for their extensive experience in the fields of hearing and tinnitus and bringing new technologies to market. Together, we share a commitment towards establishing bimodal neuromodulation as a new standard of care for tinnitus.

Team Management

Dr. Ross O’Neill PhD MBA

Founder & CEO Linkedin

Prof. Brendan Conlon ENT

Chief Medical Officer Linkedin

Dr. Hubert Lim PhD

Chief Scientific Officer Linkedin

Florian Elsaesser

Chief Finance Officer Linkedin

Diarmuid Flavin

Chief Operating Officer Linkedin

Derek Madden CPA CTax

Vice President, Finance and Corporate Governance Linkedin

Caroline Hamilton BSc (Aud) MSc (Neuro)

Audiology Director Linkedin

Eric Timm

President, Global Commercial Operations & Chief Executive Officer, Neuromod USA Linkedin

Stephanie Glowacki

Chief Financial Officer, Neuromod USA Linkedin

Tish Ramirez

Chief Commercial Officer, Neuromod USA Linkedin

Board of Directors

Dr. Ross O’Neill PhD MBA

Director Linkedin

Ross is a biomedical engineer with a personal passion for developing neuromodulation therapies for hearing and auditory system disorders. He founded Neuromod in 2010 to develop non-invasive neuromodulation treatments for chronic neurological disorders.

Dr. Manus Rogan PhD MBA

Chairman Linkedin

Manus is a chemist who began his career in drug development before moving into business development and venture capital investment, establishing Fountain Healthcare Partners in the 2000’s to invest in groundbreaking technologies in the life science sector.

Susan Whichard

Non-Executive Board Member Linkedin

Susan has more than 30 years’ experience in the hearing industry, having worked as both a business executive and a practicing clinical audiologist. She served as president of the Academy of Doctors of Audiology (ADA) from 1992-1994. She has also held many leadership roles at companies such as GN Resound, InSound Medical and Phonak US. More recently, Susan started a consulting business focused on start-up innovation in hearing and healthcare.

Alessio Beverina

Non-Executive Board Member Linkedin

Alessio is Co-Founder and General Partner of Panakès Partners, a Venture Capital fund dedicated to life sciences and headquartered in Milan, Italy with more than €250 million under management. Alessio has significant VC experience earned at Sofinnova Partners, one of Europe's largest VCs, where he progressed from Analyst to Partner positions with European and American exposure.

He began his career in 1997 as a researcher at LETI, one of the most important European labs in the research field, before joining the central R&D group of STMicroelectronics. He graduated from Politecnico di Milano, with a degree in chemical engineering, specialising in the chemistry and physics of solid materials, and with an MBA from the Ecole Supérieure de Commerce de Paris (ESCP-EAP).

Alessio is a Kauffman Fellow and sits on the board of Alesi Surgical ltd, MMI spa and Neuromod Devices ltd. Alessio is also General Secretary of the Italian Tech Alliance.


We are proud to be working with a number of partners who share and respect our vision of this game-changing therapeutic breakthrough.

  • Investment Partners
    • Fountain Healthcare
    • Enterprise Ireland
    • Moffett Investment Holdings
    • Kreos Capital
    • Silicon Valley Bank
    • Medical Device Resources
    • European Investment Bank
    • Panakès Partners
  • Notified Body
    • BSI
  • Legal Partners
    • Byrne Wallace
  • Audit and Advisory Partners
    • KPMG
  • European Patent Attorneys
    • Tomkins
  • US Patent Attorneys
    • Shay Glenn LLP